Roivant Sciences Ltd. → Arbutus Biopharma Corp ABUS

Item 4 of the Original Schedule 13D is hereby amended and restated as follows: To the extent required by Item 4, the information contained in Item 5 below is incorporated herein by reference. Roivant currently holds 38,847,462 Common Shares. Subject to applicable legal requirements, Roivant may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to Roivant's ownership of the Issuer's securities, other opportunities available to Roivant, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, Roivant may dispose of all or a portion of its securities of the Issuer at any time. Roivant reserves the right to increase or decrease its holdings on such terms and at such times as it may decide. Additionally, Roivant or subsidiaries of Roivant and the Issuer are party to several agreements, including a governance agreement and a registration rights agreement. Currently, Roivant has no plans in respect of these agreements that would involve transactions of the sort described in clauses (a) through (j) of Item 4 of Schedule 13D. Roivant and its representatives are evaluating potential near-term changes to the composition of the board of directors and management of the Issuer. Roivant's representatives may also be engaged in discussions related to such potential changes in the board of directors and management of the Issuer with other shareholders of the Issuer. Other than as described above, Roivant does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, Roivant may change its purpose or formulate different plans or proposals with respect thereto at any time.